U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07948109) titled 'YSCH-01 for Recurrent or Progressive Glioblastoma' on Nov. 01.
Brief Summary: This is an open-label dose-escalation and dose-expansion study that plans to enroll 16 to 32 adult participants with recurrent or progressive glioblastoma. Participants will be assigned to different dose groups. This study consists of two parts, namely the dose escalation stage and the dose expansion stage. The study aims to determine the safety and tolerability of the oncolytic adenovirus YSCH-01 in adult participants with recurrent or progressive glioblastoma.
Study Start Date: Nov. 10
Study Type: INTERVENTIONAL
Condition:
Recurrent Glioblastoma (WHO...